Lupin Limited, the third largest pharma company with net sales of Rs.13,700 crore plus, announced that its US subsidiary, Lupin Pharmaceuticals, Inc. (collectively Lupin) has received final approval for its desoximetasone ointment USP, 0.25% from the United States Food & Drug Administration (FDA) to market a generic version of Taro Pharmaceuticals, Inc.'s Topicort ointment, 0.25%.
Lupin’s desoximetasone ointment USP, 0.25% is the AB rated generic equivalent of Taro Pharmaceuticals, Inc.'s Topicort ointment, 0.25%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Topicort had US sales of USD 14.4 million (IMS MAT September 2016).